Navigation Links
AtheroNova Adds New Medical Advisor
Date:4/11/2013

IRVINE, Calif., April 11, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Stephen Nicholls , M.B.B.S., PhD., Heart Disease Theme leader at the South Australia Health and Medical Research Institute (SAHMRI), has been appointed as chair of the newly renamed Clinical Advisory Board, replacing the recently retired Dr. Giorgio Zadini , one of the co-founders of AtheroNova.  Dr. Nicholls will also be a Co-Principal Investigator in the Company's upcoming clinical trials.

"As we continue to make positive strides, this is a key step in our evolution from a pre-clinical to a clinical stage pharmaceutical company as we move toward entry into Phase 1 in the near future.  Dr. Nicholls brings a wealth of experience in the imaging and analysis of cardiovascular plaque as we target the treatment of both serum cholesterol as well as atherosclerosis with AHRO-001," stated Thomas W. Gardner , CEO of AtheroNova. "Dr. Nicholls' experience with clinical developments during his time at the Cleveland Clinic as well as his new role as the key theme leader in one of the premier research organizations in Australia is essential in leading our Clinical Advisory Board.  We would like to thank Dr. Zadini for all of his tremendous efforts and accomplishments as the key medical advisor of the Company during the development stage and wish him well."

"Steve is one of the world's most respected authorities in the imaging of atherosclerosis," commented Mark Wedel , M.D., Chief Medical Officer of AtheroNova.  "We are profoundly fortunate and appreciative to benefit from his leadership and expertise as we move forward.
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
2. AtheroNova Names New Director
3. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
4. AtheroNova Releases 2011 Financial Results
5. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
6. AtheroNova Announces a New Board Member
7. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
8. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
11. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced ... will provide an update on the progress of Sangamo,s ZFP ... company,s business strategy at 1:30pm ET on Monday, June 1, ... is being held in New York, NY ... may be accessed via a link on the Sangamo BioSciences ...
(Date:5/26/2015)... 26, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... Company,s Annual Meeting of Shareholders for fiscal year ended ... at the Company,s office located in Chengdu, ... AM (local time in Chengdu, China ...
(Date:5/26/2015)... , May 26, 2015   PDI ... solutions, today announced that Oakwood Healthcare in ... as the winning entry in Delivering ... professionals who display excellence in building collaborative relationships ... teams in healthcare facilities.  Oakwood ...
(Date:5/26/2015)... 2015 Leading Regenerative Veterinary Medicine® ... long-term relationship with Veterinary Growth Partners, a membership ... to provide access to vital services to veterinary ... VGP as a dedicated partner in bringing stem ... Concentrating and using stem cells natural abilities to ...
Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3
... ORLANDO, Fla. , June 26, 2010 ... Eli Lilly and Company (NYSE: LLY ) ... more than 260,000 patients that showed the risk of ... not increased compared to initiators of other antidiabetic therapies. ...
... we will use our mobile phone to buy bus and ... other European states by just presenting an electronic card or ... Most of us hate standing in queues or filling ... signatures could save hours of our time running to offices ...
... NEW YORK , June 25 /PRNewswire-Asia-FirstCall/ -- ... an international biopharmaceutical,company with operations in the U.S. and ... agreements with certain accredited,investors (the "Investors") to sell in a ... of $5 million . Each unit was,priced at ...
Cached Biology Technology:Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 2Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 3Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 4Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 5Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 6Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 7Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 8Really smart card project scoops EUREKA 2010 Innovation Award 2Really smart card project scoops EUREKA 2010 Innovation Award 3Really smart card project scoops EUREKA 2010 Innovation Award 4NeoStem Raises $5 Million in Registered Direct Offering 2NeoStem Raises $5 Million in Registered Direct Offering 3NeoStem Raises $5 Million in Registered Direct Offering 4
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... ulcerative colitis, according to a new study co-ordinated by medical ... Presented today at the Digestive Disease Week conference in New ... in oleic acid which is present in olive oil ... is a monounsaturated fatty acid found in olive oil, peanut ...
... during pregnancy is not only safe for mother and baby, ... results of a randomized controlled study to be presented at ... Columbia, Canada. In the 1950s and ,60s, people ... to Carol L. Wagner, MD, lead author of the study ...
... KY Current research suggests that tumor-secreted exosomes ... related report by Liu et al, "Contribution of MyD88 ... cells," appears in the May 2010 issue of ... system plays a critical role in identifying and destroying ...
Cached Biology News:Olive oil could guard against developing ulcerative colitis 2Researchers recommend pregnant women take 4,000 IU vitamin D a day 2
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... net results - with a modular approach ... management! The ChemStation Plus NDS family provides ... acquisition and data management, giving you the ... your labs needs now and that can ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
Biology Products: